• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy.接受有效抗逆转录病毒治疗的感染者体内残余血浆病毒血症与 HIV 前病毒 DNA 库大小的关系。
J Infect Dis. 2011 Jul 1;204(1):135-8. doi: 10.1093/infdis/jir208.
2
Lack of concordance between residual viremia and viral variants driving de novo infection of CD4(+) T cells on ART.抗逆转录病毒治疗(ART)期间,残余病毒血症与驱动CD4(+) T细胞新发感染的病毒变体之间缺乏一致性。
Retrovirology. 2016 Aug 2;13(1):51. doi: 10.1186/s12977-016-0282-9.
3
The gut mucosal viral reservoir in HIV-infected patients is not the major source of rebound plasma viremia following interruption of highly active antiretroviral therapy.在感染 HIV 的患者中,肠道黏膜病毒库并不是中断高效抗逆转录病毒治疗后血浆病毒血症反弹的主要来源。
J Virol. 2011 May;85(10):4772-82. doi: 10.1128/JVI.02409-10. Epub 2011 Feb 23.
4
Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy.抗逆转录病毒治疗时完整 HIV-1 前病毒 DNA 的选择性衰减。
J Infect Dis. 2021 Feb 3;223(2):225-233. doi: 10.1093/infdis/jiaa532.
5
Detection and quantification of proviral HIV-1 184 M/V in circulating CD4(+) T cells of patients on HAART with a viremia less than 1,000 copies/ml.在接受高效抗逆转录病毒治疗(HAART)且病毒血症低于1000拷贝/毫升的患者循环CD4(+) T细胞中检测和定量原病毒HIV-1 184 M/V 。
J Clin Virol. 2005 Dec;34(4):257-67. doi: 10.1016/j.jcv.2005.02.015. Epub 2005 Apr 18.
6
Immunologic and Virologic Parameters Associated With Human Immunodeficiency Virus (HIV) DNA Reservoir Size in People With HIV Receiving Antiretroviral Therapy.与接受抗逆转录病毒治疗的 HIV 感染者的 HIV DNA 储存库大小相关的免疫和病毒学参数。
J Infect Dis. 2024 Jun 14;229(6):1770-1780. doi: 10.1093/infdis/jiad595.
7
Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies.HIV-1 根除研究中病毒储存库测量方法的比较分析。
PLoS Pathog. 2013 Feb;9(2):e1003174. doi: 10.1371/journal.ppat.1003174. Epub 2013 Feb 14.
8
Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication.尽管 HIV 储存库水平极低,但停止抗逆转录病毒治疗后血浆病毒血症反弹:对根除的影响。
AIDS. 2010 Nov 27;24(18):2803-8. doi: 10.1097/QAD.0b013e328340a239.
9
Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy.对1型人类免疫缺陷病毒血症和静息CD4+ T细胞中前病毒的分析揭示了接受抗逆转录病毒治疗患者残余病毒血症的新来源。
J Virol. 2009 Sep;83(17):8470-81. doi: 10.1128/JVI.02568-08. Epub 2009 Jun 17.
10
Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving highly active antiretroviral therapy.低水平病毒血症和前病毒DNA阻碍接受高效抗逆转录病毒治疗的HIV-1感染患者的免疫重建。
J Infect Dis. 2005 Feb 1;191(3):348-57. doi: 10.1086/427340. Epub 2004 Dec 30.

引用本文的文献

1
Proviruses in CD4 T cells reactive to autologous antigens contribute to nonsuppressible HIV-1 viremia.对自身抗原产生反应的CD4 T细胞中的前病毒会导致无法抑制的HIV-1病毒血症。
Sci Transl Med. 2025 Aug 13;17(811):eadu4643. doi: 10.1126/scitranslmed.adu4643.
2
No associations between HIV reservoir and inflammation in long-term virally suppressed dolutegravir-based ART-treated individuals.在长期病毒抑制的基于多替拉韦的抗逆转录病毒治疗个体中,HIV储存库与炎症之间无关联。
Front Immunol. 2025 Jul 28;16:1628086. doi: 10.3389/fimmu.2025.1628086. eCollection 2025.
3
Managing low-level HIV viraemia in antiretroviral therapy: a systematic review and meta-analysis.抗逆转录病毒治疗中低水平 HIV 病毒血症的管理:系统评价和荟萃分析。
Sex Transm Infect. 2024 Oct 17;100(7):460-468. doi: 10.1136/sextrans-2024-056198.
4
Management of low-level HIV viremia during antiretroviral therapy: Delphi consensus statement and appraisal of the evidence.抗逆转录病毒治疗期间低水平 HIV 病毒血症的管理:德尔菲共识声明和证据评估。
Sex Transm Infect. 2024 Oct 17;100(7):442-449. doi: 10.1136/sextrans-2024-056199.
5
Learning from Persistent Viremia: Mechanisms and Implications for Clinical Care and HIV-1 Cure.从持续性病毒血症中学习:机制及对临床护理和 HIV-1 治愈的启示。
Curr HIV/AIDS Rep. 2023 Dec;20(6):428-439. doi: 10.1007/s11904-023-00674-w. Epub 2023 Nov 13.
6
MRP8/14 Is a Molecular Signature Triggered by Dopamine in HIV Latent Myeloid Targets That Increases HIV Transcription and Distinguishes HIV+ Methamphetamine Users with Detectable CSF Viral Load and Brain Pathology.MRP8/14 是潜伏在骨髓中的 HIV 靶细胞中多巴胺触发的分子标志物,可增加 HIV 转录,并可区分脑脊液中可检测到病毒载量和脑部病变的 HIV+ 甲基苯丙胺使用者。
Viruses. 2023 Jun 13;15(6):1363. doi: 10.3390/v15061363.
7
Impact of the first-line antiretroviral therapy on soluble markers of inflammation in cohort of human immunodeficiency virus type 1 in Moroccan patients: a prospective study.一线抗逆转录病毒疗法对摩洛哥人类免疫缺陷病毒1型患者队列炎症可溶性标志物的影响:一项前瞻性研究。
Arch Microbiol. 2023 May 8;205(6):223. doi: 10.1007/s00203-023-03574-0.
8
The Many Faces of Immune Activation in HIV-1 Infection: A Multifactorial Interconnection.HIV-1感染中免疫激活的多面性:多因素相互联系
Biomedicines. 2023 Jan 8;11(1):159. doi: 10.3390/biomedicines11010159.
9
A Dynamic Interplay of Circulating Extracellular Vesicles and Galectin-1 Reprograms Viral Latency during HIV-1 Infection.循环细胞外囊泡与半乳糖凝集素-1 的动态相互作用在 HIV-1 感染期间重塑病毒潜伏期。
mBio. 2022 Aug 30;13(4):e0061122. doi: 10.1128/mbio.00611-22. Epub 2022 Aug 9.
10
Intact HIV Proviruses Persist in the Brain Despite Viral Suppression with ART.尽管采用抗逆转录病毒疗法(ART)进行了病毒抑制,但 HIV 前病毒仍存在于大脑中。
Ann Neurol. 2022 Oct;92(4):532-544. doi: 10.1002/ana.26456. Epub 2022 Aug 9.

本文引用的文献

1
Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy.在接受抑制性抗逆转录病毒治疗的 HIV 阳性患者的肠道内,HIV 负担和免疫激活存在差异。
J Infect Dis. 2010 Nov 15;202(10):1553-61. doi: 10.1086/656722. Epub 2010 Oct 12.
2
Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.在接受抑制性抗逆转录病毒治疗的 HIV 阳性成年人的多个肠道部位,含拉替拉韦的强化治疗对 HIV 负荷和 T 细胞激活的影响。
AIDS. 2010 Oct 23;24(16):2451-60. doi: 10.1097/QAD.0b013e32833ef7bb.
3
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.拉替拉韦强化治疗对接受抗逆转录病毒治疗的 HIV 感染患者低水平残留病毒血症的影响:一项随机对照试验。
PLoS Med. 2010 Aug 10;7(8):e1000321. doi: 10.1371/journal.pmed.1000321.
4
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.整合酶抑制剂拉替拉韦强化治疗可影响 HIV-1 复制和免疫动力学。
Nat Med. 2010 Apr;16(4):460-5. doi: 10.1038/nm.2111. Epub 2010 Mar 14.
5
Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy.对于接受高效抗逆转录病毒治疗的患者,强化治疗并不能降低残留的HIV-1病毒血症。
Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9403-8. doi: 10.1073/pnas.0903107106. Epub 2009 May 22.
6
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy.接受抑制性抗逆转录病毒治疗的患者中,低水平病毒血症至少持续7年。
Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3879-84. doi: 10.1073/pnas.0800050105. Epub 2008 Mar 10.
7
Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy.尽管进行了长期抗逆转录病毒治疗,但HIV仍在肠道相关淋巴组织中持续存在。
J Infect Dis. 2008 Mar 1;197(5):714-20. doi: 10.1086/527324.
8
ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia.抗逆转录病毒疗法将血浆中的HIV-1 RNA抑制到由治疗前病毒血症预测的稳定水平。
PLoS Pathog. 2007 Apr;3(4):e46. doi: 10.1371/journal.ppat.0030046.
9
Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells.接受抗逆转录病毒治疗的一些患者体内的残余1型人类免疫缺陷病毒血症,由循环CD4+ T细胞中罕见的少数不变克隆所主导。
J Virol. 2006 Jul;80(13):6441-57. doi: 10.1128/JVI.00591-06.
10
The survival benefits of AIDS treatment in the United States.美国艾滋病治疗的生存益处。
J Infect Dis. 2006 Jul 1;194(1):11-9. doi: 10.1086/505147. Epub 2006 Jun 1.

接受有效抗逆转录病毒治疗的感染者体内残余血浆病毒血症与 HIV 前病毒 DNA 库大小的关系。

Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy.

机构信息

Laboratory of Immunoregulation, National Institutes of Health, Bethesda, MD, USA.

出版信息

J Infect Dis. 2011 Jul 1;204(1):135-8. doi: 10.1093/infdis/jir208.

DOI:10.1093/infdis/jir208
PMID:21628667
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3105034/
Abstract

Residual plasma viremia (<50 copies/mL) persists in certain human immunodeficiency virus (HIV)-infected individuals receiving antiretroviral therapy (ART); however, the relationship between the degree of residual plasma viremia, the size of HIV reservoirs, and the level of immune activation has not been delineated. Here, we demonstrate that residual plasma viremia correlates with the size of the CD4(+) T cell viral reservoir, but not with markers of immune activation, suggesting that reactivation of the latent viral reservoir may not be the sole source of residual plasma viremia. Novel therapeutic strategies aimed at targeting the source of residual viremia may be necessary to achieve viral eradication.

摘要

在接受抗逆转录病毒治疗 (ART) 的某些人类免疫缺陷病毒 (HIV) 感染者中,仍存在残余血浆病毒血症(<50 拷贝/毫升);然而,残余血浆病毒血症的程度、HIV 储存库的大小以及免疫激活水平之间的关系尚未明确。在这里,我们证明残余血浆病毒血症与 CD4(+) T 细胞病毒储存库的大小相关,但与免疫激活标志物无关,这表明潜伏病毒储存库的重新激活可能不是残余血浆病毒血症的唯一来源。可能需要针对残余病毒血症来源的新型治疗策略来实现病毒清除。